Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed roundFunds will be used to accelerate a new generation of T cell therapies against solid tumors...

Pan Cancer T appoints Rachel Abbott to succeed Katrien Reynders-Frederix as Chief Executive Officer ROTTERDAM, May 12, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the...

Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer - Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...